A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


May 29, 2012

Adherence Challenges in Intermittent HIV PrEP Study

by Tim Horn

Intermittent use of Truvada (tenofovir plus emtricitabine) as pre-exposure prophylaxis was associated with poor adherence, compared with daily use of the tablet to prevent HIV infection, according to results of a small clinical trial published in the online scientific journal PLoS ONE.

Using electronic pill caps, the Kenyan study found that the adherence rate associated with daily PrEP use was 83 percent. Among those using intermittent therapy—Truvada taken on Monday, Friday and within two hours following sexual intercourse—the adherence rate was 55 percent. Among those who only took Truvada within two hours following sexual intercourse, the post-coital adherence rate was only 26 percent.

Truvada as PrEP was recently recommended for U.S. Food and Drug Administration (FDA) approval by the Antiviral Drugs Advisory Committee. The recommendation is based on data from several clinical trials, all exploring the safety and efficacy of Truvada PrEP used daily.

There has been interest in exploring alternative dosing strategies, notably scheduled and as-needed intermittent use of the drug. Experts hypothesize less frequent dosing may reduce the risk of side effects and prove easier for people to use, in light of the poor adherence that has been noted in clinical trials evaluating daily use of Truvada.

Preliminary results from a study involving 67 African men who have sex with men (MSM) and five female sex workers were reported at the International AIDS Conference. The final study report was authored by Gaudensia Mutua, MD, of the Kenya AIDS Vaccine Initiative and her colleagues and published by PLoS ONE in April.

The intermittent PrEP strategies appeared to be safe and well tolerated. Ninety-seven percent of the side effects reported were mild to moderate in severity, and 91 percent were judged by the researchers to be unrelated to the use of Truvada.

Mild creatinine elevations—a possible sign of Truvada kidney toxicity—were documented in three study volunteers receiving the drug, though all resolved spontaneously over the duration of the study. Two cases of abnormal creatinine clearance, another potential sign of Truvada-related kidney impairment, were reported in one Truvada-treated study volunteer and one placebo-treated study volunteer. These irregularities also resolved spontaneously, and no other clinically significant signs of kidney dysfunction were documented.

One HIV infection occurred in a volunteer in the placebo group at week 16.

Adherence to the study drug regimens in this trial was measured using the medication event monitoring system (MEMS)—electronic pill caps that record each instance in which the pill container is opened—as well as monthly follow-up interviews.

Daily text messages were used to collect data on sexual behavior in order to estimate post-intercourse PrEP adherence. “The lower adherence rate to the post-coital doses in the intermittent regimen suggests that post-coital dosing may be challenging in the populations included in this trial,” explains the International AIDS Vaccine Initiative (IAVI), a developer of the study, in a news announcement. “However it may also reflect difficulties in accurately measuring post-coital dosing using MEMS or self-report data.  

“Further study will be needed to determine whether the intermittent use of Truvada as pre-exposure prophylaxis will be a viable HIV-prevention strategy for MSM and female sex workers in Africa,” IAVI suggests. “Currently, few studies address adherence to non-daily medication regimens, and these findings will be useful to future studies examining the intermittent use of PrEP for HIV prevention.”

Search: hiv, prep, pre-exposure prophylaxis, prevention, transmission, adherence, intermittent, coital, kenya, plos one

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.